Vascular graft infections are a particularly troublesome complication for
dialysis patients, many of whom are in an already immunocompromised state. The
objective of this review is to detail the risk factors, etiology, diagnosis,
perioperative and operative management of vascular graft infections.
PisoniRLZepelLPortFKRobinsonBMTrends in US vascular access use, patient preferences, and
related practices: an update from the US DOPPS practice monitor with
international comparisons.Am J Kidney Dis2015656905–915
2.
RyanSVCalligaroKDDoughertyMJManagement of hemodialysis access infections.Semin Vasc Surg200417140–44
3.
JaberBLBacterial infections in hemodialysis patients: pathogenesis and
prevention.Kidney Int20056762508–2519
4.
SarnakMJJaberBLMortality caused by sepsis in patients with end-stage renal
disease compared with the general population.Kidney Int20005841758–1764
5.
AndersonJEChangASAnstadtMPPolytetrafluoroethylene hemoaccess site
infections.ASAIO J2000466S18–S21
6.
MingaTEFlanaganKHAllonMClinical consequences of infected arteriovenous grafts in
hemodialysis patients.Am J Kidney Dis2001385975–978
7.
LewSQKavehKDialysis access related infections.ASAIO J2000466S6–S12
8.
TabbaraMRO'HaraPJHertzerNRKrajewskiLPBevenEGSurgical management of infected PTFE hemodialysis grafts:
analysis of a 15-year experience.Ann Vasc Surg199594378–384
9.
AkohJAPatelNInfection of hemodialysis arteriovenous grafts.J Vasc Access2010112155–158
BrockJSSussmanMWamsleyMMintzerRBaumannFGRilesTSThe influence of human immunodeficiency virus infection and
intravenous drug abuse on complications of hemodialysis access
surgery.J Vasc Surg1992166904–910discussion 911-912.
15.
LeeHKParkJHKimESKimHSHanSYArteriovenous thrombosis due to Aspergillus in a patient with
hemodialysis.J Vasc Access2013142204
16.
SextonDJVascular access infections in patients undergoing dialysis with
special emphasis on the role and treatment of Staphylococcus
aureus.Infect Dis Clin North Am2001153731–742
17.
TaylorBSigleyRDMayKJFate of infected and eroded hemodialysis grafts and autogenous
fistulas.Am J Surg19931655632–636
18.
SchildAFSimonSPrietoJRainesJSingle-center review of infections associated with 1,574
consecutive vascular access procedures.Vasc Endovascular Surg200337127–31
19.
WalzPLadowskiJSPartial excision of infected fistula results in increased patency
at the cost of increased risk of recurrent infection.Ann Vasc Surg200519184–89
20.
RyanSVCalligaroKDScharffJDoughertyMJManagement of infected prosthetic dialysis arteriovenous
grafts.J Vasc Surg200439173–78
21.
LegoutLD'EliaPVSarraz-BournetBet al.Diagnosis and management of prosthetic vascular graft
infections.Med Mal Infect2012423102–109
22.
AyusJCSheikh-HamadDSilent infection in clotted hemodialysis access
grafts.J Am Soc Nephrol1998971314–1317
23.
CeppaEPSileshiBBeasleyGMLawsonJHSurgical excision of infected arteriovenous grafts: technique and
review.J Vasc Access2009103148–152
24.
DeneuvilleMInfection of PTFE grafts used to create arteriovenous fistulas
for hemodialysis access.Ann Vasc Surg2000145473–479
25.
RajuSPTFE grafts for hemodialysis access.Techniques for insertion and management of complications. Ann
Surg19872065666–673
26.
SchanzerACiaranelloALSchanzerHBrachial artery ligation with total graft excision is a safe and
effective approach to prosthetic arteriovenous graft
infections.J Vasc Surg2008483655–658
27.
SchutteWPHelmerSDSalazarLSmithJLSurgical treatment of infected prosthetic dialysis arteriovenous
grafts: total versus partial graft excision.Am J Surg20071933385–388discussion 388.
28.
TanYMTanSGEmergency ligation of the brachial artery for complications of
vascular access.Br J Surg2005922244–245
29.
ThomasGWRaelLTBar-OrRet al.Mechanisms of delayed wound healing by commonly used
antiseptics.J Trauma20096682–90discussion 90-91.
30.
GiffordRRManagement of tunnel infections of dialysis
polytetrafluoroethylene grafts.J Vasc Surg198526854–858
31.
BhatDJTellisVAKohlbergWIDriscollBVeithFJManagement of sepsis involving expanded polytetrafluoroethylene
grafts for hemodialysis access.Surgery1980874445–450
32.
HatzibaloglouAVelissarisIKaitzisDGrekasDAvdelidouAKiskinisDProCol vascular bioprosthesis for vascular access: midterm
results.J Vasc Access20045116–18
33.
WidmerMKAreggerFStaufferEet al.Intermediate outcome and risk factor assessment of bovine
vascular heterografts used as AV-fistulas for hemodialysis
access.Eur J Vasc Endovasc Surg2004276660–665
34.
BozoglanOMeseBErogluEet al.Which prosthesis is more resistant to vascular graft infection:
polytetrafluoroethylene or Omniflow II biosynthetic grafts?Surg Today2015Epub ahead of print.
35.
PalumboRNiscolaPCalabriaSet al.Long-term favorable results by arteriovenous graft with Omniflow
II prosthesis for hemodialysis.Nephron Clin Pract20091132c76–c80
36.
TöpelIBetzTUhlCWiesnerMBröcknerSSteinbauerMUse of biosynthetic prosthesis (Omniflow II®) to replace
infected infrainguinal prosthetic grafts—first
results.Vasa2012413215–220
37.
MatsuuraJHJohansenKHRosenthalDClarkMDClarkeKAKirbyLBCryopreserved femoral vein grafts for difficult hemodialysis
access.Ann Vasc Surg200014150–55
38.
MatsuuraJHRosenthalDWellonsEDCastronovoCSFronkDHemodialysis graft infections treated with cryopreserved femoral
vein.Cardiovasc Surg2002106561–565
39.
BoltonWDCullDLTaylorSMet al.The use of cryopreserved femoral vein grafts for hemodialysis
access in patients at high risk for infection: a word of
caution.J Vasc Surg2002363464–468
40.
BenedettoBLipkowitzGMaddenRet al.Use of cryopreserved cadaveric vein allograft for hemodialysis
access precludes kidney transplantation because of
allosensitization.J Vasc Surg2001341139–142
41.
WystrychowskiWMcAllisterTNZagalskiKDusserreNCierpkaLL'HeureuxNFirst human use of an allogeneic tissue-engineered vascular graft
for hemodialysis access.J Vasc Surg20146051353–1357
42.
ValletCSaucyFHallerCMeierPRafoulWCorpatauxJMVacuum-assisted conservative treatment for the management and
salvage of exposed prosthetic hemodialysis access.Eur J Vasc Endovasc Surg2004284397–399
43.
DosluogluHHSchimpfDKSchultzRCherrGSPreservation of infected and exposed vascular grafts using vacuum
assisted closure without muscle flap coverage.J Vasc Surg2005425989–992
44.
ShahASValdesJCharlton-OuwKMet al.Endovascular treatment of hemodialysis access
pseudoaneurysms.J Vasc Surg20125541058–1062
45.
ShemeshDGoldinIZaghalIBerelowitzDVerstandigAGOlshaOStent graft treatment for hemodialysis access
aneurysms.J Vasc Surg20115441088–1094
46.
KimCYGuevaraCJEngstromBIet al.Analysis of infection risk following covered stent exclusion of
pseudoaneurysms in prosthetic arteriovenous hemodialysis access
grafts.J Vasc Interv Radiol201223169–74
47.
KeelingWBMyersARStonePAet al.Regional antibiotic delivery for the treatment of experimental
prosthetic graft infections.J Surg Res20091572223–226
48.
BandykDFNovotneyMLJohnsonBLBackMRRothSRUse of rifampin-soaked gelatin-sealed polyester grafts for in
situ treatment of primary aortic and vascular prosthetic
infections.J Surg Res200195144–49
49.
GaoHSandermannJPragJLundLLindholtJSRifampicin-soaked silver polyester versus expanded
polytetrafluoro-ethylene grafts for in situ replacement of infected grafts
in a porcine randomised controlled trial.Eur J Vasc Endovasc Surg2012435582–587
50.
Goëau-BrissonnièreOJaverliatIKoskasFCoggiaMPechèreJCRifampin-bonded vascular grafts and postoperative
infections.Ann Vasc Surg2011251134–142
51.
JaverliatIGoëau-BrissonnièreOBrunevalPCoggiaMExperimental study of a new vascular graft prebonded with
antibiotic: healing, toxicity, and antibiotic retention.Ann Vasc Surg2007215603–610
52.
JaverliatIGoëau-BrissonnièreOSivadon-TardyVCoggiaMGaillardJLPrevention of Staphylococcus aureus graft infection by a new
gelatin-sealed vascular graft prebonded with antibiotics.J Vasc Surg20074651026–1031
53.
SacarMGoksinIBaltalarliAet al.The prophylactic efficacy of rifampicin-soaked graft in
combination with systemic vancomycin in the prevention of prosthetic
vascular graft infection: an experimental study.J Surg Res20051292329–334
54.
AkohJAVascular access infections: epidemiology, diagnosis, and
management.Curr Infect Dis Rep2011134324–332
